Panbela Therapeutics (Nasdaq: PBLA) announced a conference call on August 15, 2022, to discuss its second-quarter results for the period ended June 30, 2022. The company is focused on developing therapeutics for serious unmet medical needs, with ongoing clinical trials for SBP-101 and Flynpovi. SBP-101 has shown a median overall survival of 14.6 months in pancreatic cancer patients, while Flynpovi demonstrated over 90% effectiveness in preventing pre-cancerous adenomas in a Phase 3 trial. The call will start at 4:30 PM ET.
Panbela Therapeutics announced promising preclinical data for its drug SBP-101, showing a 42% increase in median survival in a mouse model of ovarian cancer. In vitro studies demonstrated significant reduction in viability across multiple cancer cell types. The company plans to launch a clinical program for SBP-101 in ovarian cancer in 2022, complementing its existing global trial for pancreatic cancer. SBP-101's promising results include a median overall survival of 14.6 months in pancreatic cancer patients, with an objective response rate of 48%.
Panbela Therapeutics announced the successful acquisition of Cancer Prevention Pharmaceuticals for a mix of stock and milestone payments. This merger targets a $5 billion market opportunity, focusing on cancer types including familial adenomatous polyposis and pancreatic cancer. The acquisition aims to enhance their clinical pipeline by integrating four clinical-stage assets, among which two are late-stage. This strategic move is expected to bolster shareholder value and improve treatment options for patients.
Panbela Therapeutics (Nasdaq: PBLA) provided a business update and financial results for Q1 2022, highlighted by a net loss of $3.7 million, or $0.27 per diluted share. Key developments included the agreement to acquire Cancer Prevention Pharmaceuticals (CPP) targeting a $5 billion market, the initiation of the ASPIRE trial for SBP-101 in pancreatic cancer, and a successful R&D Day presentation. General and administrative expenses rose to $1.8 million, while research and development costs increased to $2.2 million due to the ASPIRE trial launch.
Panbela Therapeutics (Nasdaq: PBLA) will host an R&D call on May 03, 2022, at 9:00 AM ET, featuring experts discussing the investigational drug SBP-101 for ovarian cancer treatment. The drug is a polyamine metabolism modulator showing promise in clinical studies, achieving a median overall survival of 12.0 months and an objective response rate of 48% in pancreatic cancer patients. The call is accessible via toll-free numbers and a provided event link. Replay details will also be available post-event.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) will host a conference call on May 12, 2022, at 4:30 PM ET to discuss its first-quarter results for the period ending March 31, 2022. The company is advancing SBP-101, a therapeutic designed for pancreatic cancer treatment, showing a median overall survival of 12 months and an objective response rate of 48% in clinical trials. Interested parties can join via phone or webcast. For further details, visit www.panbela.com.
Panbela Therapeutics (Nasdaq: PBLA) has presented promising results for SBP-101, a polyamine metabolism modulator, in treating ovarian cancer at the AACR Annual Meeting 2022. The study, conducted in collaboration with Johns Hopkins University, showed that SBP-101 significantly prolonged survival and reduced tumor burden in a murine model. The treatment demonstrated significant efficacy at doses of 24 mg/kg and 6 mg/kg. The data reveals SBP-101's potential in clinical management, with expectations to advance ovarian cancer studies later this year.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announced significant corporate and financial progress in its latest update on March 24, 2022. Key highlights include an agreement to acquire Cancer Prevention Pharmaceuticals, Inc., enhancing its pipeline targeting a $5 billion market. The company initiated the ASPIRE Phase II/III trial for its drug SBP-101 and plans to expand its development into ovarian cancer. Financially, the company reported a Q4 net loss of $3.5 million, with total cash of $11.9 million. Management expresses optimism for future growth through ongoing trials and acquisitions.
Panbela Therapeutics (Nasdaq: PBLA) announced participation in a panel discussion titled, "Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology," at the Maxim Virtual Growth Conference on March 28, 2022. The event starts at 12:00 pm ET and will stream virtually from March 28-30, 2022, featuring an on-demand presentation by the company. Their product candidate, SBP-101, has shown promising results in clinical studies with a median overall survival of 12.53 months and an objective response rate of 48%, indicating potential advantages over standard chemotherapy.
Panbela Therapeutics (Nasdaq: PBLA) announced participation in the 34th Annual Roth Conference on March 14, 2022, at 11:30 AM PT, with a webcast available online. The company is focused on developing SBP-101, a proprietary therapy for metastatic pancreatic ductal adenocarcinoma, showing promising clinical results including a median overall survival of 12 months and an objective response rate of 48%. Panbela aims to address urgent medical needs in cancer treatment, with significant potential for future development.